SynSilico
SynSilico is a Netherlands-based AI-driven in silico R&D joint venture (founded 2024 by InnoSyn and Genzai) that delivers AI-enabled computational chemistry tools — including the INNOptimizer® Bayesian Optimization platform and SynTaste™ — to pharma, chemicals, biotech, and flavor & fragrance enterprises.
- Company typePrivate
- Founded2024
- HeadquartersGeleen, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What SynSilico does
SynSilico is a Netherlands-based AI-driven in silico R&D company, headquartered in Geleen and founded in 2024 as a joint venture between InnoSyn and Genzai. The company delivers tailored AI-enabled in silico solutions for life science, chemical, and material science clients, combining machine learning workflows with bio/chemical domain expertise and optional wet lab validation. Its core product portfolio includes INNOptimizer® — a Bayesian Optimization tool available via web interface and API for integration into Self Driving Lab applications — and SynTaste™, an AI platform for flavor and fragrance discovery launched in September 2025. Underpinning these products is a proprietary server and supercomputer infrastructure capable of running over 500,000 in silico docking experiments per month with top-tier data security.
The company serves four primary verticals: Pharma (drug discovery acceleration), Chemicals & Materials (polymer performance prediction), Biotech (enzyme discovery and biocatalysis optimization, deepened through the September 2025 partnership with InnoSyn), and Flavor & Fragrance (taste and fragrance compound discovery). Its go-to-market is sales-led and direct to enterprise, combining consultative AI solution engagements with the productized INNOptimizer/Optimizer platform. Pricing is quote-based and not publicly disclosed.
Operationally, SynSilico operates with 1-10 employees across a specialized leadership team of eight including CEO Daniel Mink, CTO Roy Lenders, CSO Martin Schürmann, Managing Director Oliver May, and Directors covering Data Science & AI, Protein & Drug Design, Computational Biochemistry, and Software Engineering. The company is privately held (SynSilico B.V.), has no disclosed external funding rounds, and reports no named customer logos in the source material.
SynSilico firmographics
Firmographics- Name
- SynSilico
- Legal name
- SynSilico B.V.
- Website
- https://synsilico.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SynSilico is a Netherlands-based AI-driven in silico R&D joint venture (founded 2024 by InnoSyn and Genzai) that delivers AI-enabled computational chemistry tools — including the INNOptimizer® Bayesian Optimization platform and SynTaste™ — to pharma, chemicals, biotech, and flavor & fragrance enterprises.
- Ownership category
- akta.pro rank
SynSilico industry classification
Industry- Product category
- AI-Driven Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Small-Molecule API Process Development & Route Scouting (HLAGAHAA)
Keywords
Where SynSilico is headquartered
LocationHeadquarters
- HQ city
- Geleen
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
SynSilico business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- AI Solutions and Services: SynSilico provides tailored AI-driven solutions for Life Science, Chemical and Material Science companies, likely through project-based engagements or service contracts combining computational tools with scientific expertise.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
SynSilico product offering
Product offeringCore offering
SynSilico develops AI-driven in silico solutions that combine proprietary computational chemistry tools with deep biology and chemistry expertise to accelerate research and development for the pharmaceutical, chemicals, materials, biotechnology, and flavor & fragrance industries. The platform pairs generative AI, Bayesian optimization, and high-throughput molecular docking with optional wet-lab validation to design novel molecules, optimize enzymes and proteins, and predict sensory properties.
Product overview
SynSilico is a Geleen (NL)-based joint venture founded by InnoSyn and Genzai in 2024, delivering tailored AI-driven solutions for Life Science and Chemical industries by combining cutting-edge AI-enabled in silico tools with bio/chemical expertise. The company's product portfolio includes SynSilico Optimizer/INNOptimizer® (a Bayesian optimization platform accessible via web interface and API for automating experimental design), and SynTaste™ (an AI-powered platform for flavor and fragrance discovery). SynSilico supports industries including Pharma, Chemicals & Materials, Biotech, and Flavor & Fragrance through three core capabilities: AI models for predictive accuracy, high-performance computing infrastructure running over 500,000 in silico docking experiments monthly, and expert-driven chemical/biological validation with wet lab options.
Differentiator
Problem solved
Functional benefit
Brands
- INNOptimizer®: Bayesian Optimization tool providing easy access for Scientists dealing with challenging optimization tasks, including process, recipe, and material properties optimization.
- SynTaste™
- SynSilico Optimizer
Products and services
- INNOptimizer® (SynSilico Optimizer)
- SynTaste™
Quantifiable outcome
- Over 500,000 in silico docking experiments per month with top-tier data security
Companies that use SynSilico
Customer profileSegments4 records
Ideal customer profiles3 records
SynSilico technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
SynSilico partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- InnoSyncoreInnoSyn and SynSilico have joined forces in enzyme engineering. SynSilico's computational enzyme engineering capabilities combined with InnoSyn's biocatalysis expertise at scale captures the full potential of enzymes. This partnership integrates computational design with InnoSyn's end-to-end offerings including enzyme discovery, protein engineering, fermentation, and scale-up services, with wet lab validation in their Geleen facility covering over 30 enzyme processes.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
SynSilico competitors and assessment
Company assessmentDirect peers
- Citrine Informatics: Citrine Informatics provides AI platform for materials and chemicals R&D, including formulation and polymer optimization. Directly comparable to SynSilico's Chemicals & Materials vertical and INNOptimizer-style process/recipe optimization offering.
- BenevolentAI: BenevolentAI is an AI drug discovery company using machine learning on biomedical knowledge graphs to identify novel targets and drug candidates. Directly comparable to SynSilico's pharma-focused AI in silico offering, but with stronger emphasis on target identification.
- Cradle Bio: Cradle applies generative AI to protein engineering and biocatalyst optimization, offering wet-lab validated model outputs. Directly comparable to SynSilico's enzyme engineering work via partnership with InnoSyn and SynTaste-style generative biology offerings.
- Recursion Pharmaceuticals: Recursion applies AI and high-throughput experimentation to drug discovery at scale. Directly comparable as an AI-first drug discovery platform, though focused more on phenotypic screening and image-based biology than SynSilico's in silico chemistry and process optimization.
- Iambic Therapeutics (formerly Entos): Iambic develops AI-driven platform for rapid small molecule drug design. Directly comparable to SynSilico's AI-enabled molecular design and docking-heavy in silico workflows serving pharma R&D teams.
- Atomwise: Atomwise develops AI-driven small molecule discovery platforms (AtomNet) used by pharma and academic partners. Directly comparable to SynSilico's docking-heavy in silico drug discovery and enzyme engineering offering, with established pharma collaborations.
- XtalPi: XtalPi combines AI, quantum physics, and robotics for drug discovery and materials R&D. Comparable to SynSilico in combining high-throughput computation with experimental validation across pharma and advanced materials customers.
- Schrödinger, Inc. Schrödinger is a leading computational chemistry and AI-driven molecular design platform serving pharma and materials science. Directly comparable to SynSilico in using physics-based simulation and ML for drug discovery, with broader scale and longer track record.
- Insilico Medicine: Insilico Medicine is a global AI drug discovery company combining generative biology, chemistry, and clinical development. Directly comparable to SynSilico in offering AI-enabled in silico small molecule and target discovery for pharma, at significantly larger scale.
Emerging players
- Kebotix: Kebotix combines AI and robotics to discover and develop new chemicals and materials, with overlapping focus on generative chemistry and polymer optimization relevant to SynSilico's Chemicals & Materials vertical.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
SynSilico social profiles
Digital presenceSynSilico financial estimates
Financial estimateRevenue estimate
Valuation estimate
SynSilico leadership team
Management profileNumber of profiles
Profiles7 records
SynSilico funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SynSilico M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SynSilico
What does SynSilico do?
SynSilico develops AI-driven in silico solutions that combine proprietary computational chemistry tools with deep biology and chemistry expertise to accelerate research and development for the pharmaceutical, chemicals, materials, biotechnology, and flavor & fragrance industries. The platform pairs generative AI, Bayesian optimization, and high-throughput molecular docking with optional wet-lab validation to design novel molecules, optimize enzymes and proteins, and predict sensory properties.
Is SynSilico a public or private company?
SynSilico is a private company. It is classified as corporate owned and is currently operating.
When was SynSilico founded?
SynSilico was founded in 2024. It employs 1 to 10 people.
Where is SynSilico based?
SynSilico is headquartered in Geleen, Netherlands, in the Europe region.
How does SynSilico make money?
One revenue line is on record: AI Solutions and Services.
Who are SynSilico's main competitors?
Direct peers on record are Citrine Informatics, BenevolentAI, Cradle Bio, Recursion Pharmaceuticals, Iambic Therapeutics (formerly Entos), Atomwise, XtalPi, Schrödinger, Inc. and Insilico Medicine. Kebotix is listed as an emerging player.
Does SynSilico have an API?
Yes. INNOptimizer provides an API enabling integration with Self Driving Lab applications. The API allows scientists dealing with challenging optimization tasks to programmatically access the Bayesian optimization tool.
What industry is SynSilico in?
SynSilico's product category is AI-Driven Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2833.